PLG

Across TCGA pan-cancer cohorts, PLG Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PLG data layer compared with 21 for mass-spec protein and 9 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PLG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLG expression acts as an unfavorable survival marker.

CESC, BLCA, and ESCA are the cancer types where PLG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
BLCA	OS	Median	III,IV	0.117	0.684	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.162	0.498	.015	12	view →
COAD	DFS	Median	III,IV	0.035	0.698	<.001	9	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PLG–CESC (DFS)

Open the CESC breakdown →